Title
Consensus statement on the need for innovation, transition and implementation of developmental neurotoxicity (DNT) testing for regulatory purposes.

Permalink
https://escholarship.org/uc/item/8g38c80h

Journal
Toxicology and applied pharmacology, 354(Mem. Inst. Oswaldo Cruz 111 12 2016)

ISSN
0041-008X

Authors
Fritsche, Ellen
Grandjean, Philippe
Crofton, Kevin M
et al.

Publication Date
2018-09-01

DOI
10.1016/j.taap.2018.02.004

Peer reviewed
Consensus statement on the need for innovation, transition and implementation of developmental neurotoxicity (DNT) testing for regulatory purposes

Ellen Fritsche, Philippe Grandjean, Kevin M. Crofton, Michael Aschner, Alan Goldberg, Tuula Heinonen, Ellen V.S. Hessel, Helena T. Hogberg, Susanne Hougaard Bennekou, Pamela J. Lein, Marcel Leist, William R. Mundy, Martin Paparella, Aldert H. Piersma, Magdalini Sachana, Gabriele Schmuck, Roland Solecki, Andrea Terron, Florianne Monnet-Tschudi, Martin F. Wilks, Hilda Witters, Marie-Gabrielle Zurich, Anna Bal-Price

ARTICLE INFO

Keywords:
Developmental neurotoxicity
In vitro testing
Regulatory purposes

ABSTRACT

This consensus statement voices the agreement of scientific stakeholders from regulatory agencies, academia and industry that a new framework needs adopting for assessment of chemicals with the potential to disrupt brain development. An increased prevalence of neurodevelopmental disorders in children has been observed that cannot solely be explained by genetics and recently pre- and postnatal exposure to environmental chemicals has been suspected as a causal factor. There is only very limited information on neurodevelopmental toxicity, leaving thousands of chemicals, that are present in the environment, with high uncertainty concerning their developmental neurotoxicity (DNT) potential. Closing this data gap with the current test guideline approach is not feasible, because the in vivo bioassays are far too resource-intensive concerning time, money and number of animals. A variety of in vitro methods are now available, that have the potential to close this data gap by permitting mode-of-action-based DNT testing employing human stem cells-derived neuronal/glial models. In vitro DNT data together with in silico approaches will in the future allow development of predictive models for...
There is no doubt that an optimally developed brain is a profound asset to human functioning as well as for the sustainability and intellectual depth of any society. The human brain is by far the most advanced and complex brain in the animal world with regard to both its structure and functionality. Although brain development in all vertebrate species starts from a small tube of neuroectoderm, human embryonic brain development proceeds in a more complex manner than any other species. The human brain develops through a series of developmental stages that must occur in a particular sequence and at the right time. The final outcome on the human brain is critically dependent upon the physiology of these processes, each of which might be vulnerable to adverse effects from exposures to environmental chemicals or drugs.

A report by the US National Research Council (NRC) clearly documents the challenges in using rodent-based testing in general, to predict adverse outcomes in humans (NRC, 2007). Given extensive interspecies differences in brain morphology and function, based on specific cellular and molecular characteristics (Gassmann et al., 2010; Harrill et al., 2011; Baumann et al., 2016; Dach et al., 2017), and the paucity of chemicals tested for DNT (Makris et al., 2009; Tsuji and Crofton, 2012; Tohyama, 2016) the current reliance on DNT testing in rodents to predict effects in humans is called into question. While the US Environmental Protection Agency (OPPTS 870.630) and the Organization for Economic Co-operation and Development (OECD TG426) DNT study guidelines exist (US EPA, 1998; OECD, 2007), including guidance for interpreting DNT data in support of a pesticide registration developed by the US EPA and Health Canada (Moser et al., 2016), no routine testing for DNT is carried out in the U.S., in the EU, or elsewhere, as DNT testing is not required by law unless triggered by neurotoxic or endocrine effects in adult rodents. These triggers may not be sufficient (Sol-Price et al., 2018a) as some neurodevelopmental processes are not present in the adult brain (Fritsche et al., 2017). At the same time, performance of the DNT in vivo guideline studies involves the use of large numbers of animals and is therefore cost- and time-intensive (Crofton et al., 2012; Tohyama, 2016). These facts may contribute to the reason why only a few environmental substances (12 in total) are classified as human developmental neurotoxicants (Evans et al., 2016; Grandjean and Landrigan, 2006; Bjorling-Poulsen et al., 2008).

As a consequence of the large knowledge gaps on possible neurodevelopmental toxicity of chemicals, it is highly uncertain whether we are adequately protecting the health of our children’s brains. This issue has been recently discussed among scientists and they came to the conclusion that a new framework must be adopted for assessing chemicals that have the potential to disrupt brain development and control the use of those that may pose a risk (Bennett et al., 2016; OECD, 2017; Fritsche et al., 2017).

The rise in neurodevelopmental impairments (e.g., autism, cognitive functions, ADHD, dyslexia) among infants and children has been suspected to be caused by chemicals and/or other stressors including nutrition, stress, and gene-environment interactions (Julvez and Grandjean, 2013; Grandjean and Landrigan, 2014; McDonald and Paul, 2010; Grandjean et al., 2017; Washington State Departments of Ecology and Health, 2009).

It is now well accepted that humans have the potential to be exposed to thousands of man-made compounds (Egeghy et al., 2016; Isaacs et al., 2016) and the fact that only a small percentage of environmental contaminants have been tested for DNT, results in a critical and urgent need to develop a cost-efficient standardized alternative approach. Many methods are now available or under development both in vitro and in silico, that enable the study of human-specific molecular and cellular effects of chemicals, and their integration into in silico predictive models for developmental neurotoxicity (e.g., in vitro neuronal/glial models derived from human stem cells, (QISARs, read-across and in silico models) (Bal-Price et al., 2015; van Thriel et al., 2012; Aschner et al., 2017; OECD, 2017).

Due to the existing deficiencies in knowledge on the DNT potential of many thousands of chemical compounds (NRC, 1984; Makris et al., 2009; Tohyama, 2016), which for practical reasons cannot be overcome by the current regulatory DNT guideline studies, initiatives are ongoing that promote the development of time- and cost-effective integrative DNT strategies for regulatory purposes (Bal-Price et al., 2012, 2015, 2018a; Crofton et al., 2014; Smirnova et al., 2014; Schmidt et al., 2017). Though many reservations still exist precluding a straightforward replacement of animal testing, available data from cost- and time-efficient in vitro and lower organism models are already available, calling for consideration of their regulatory application and acceptance.

With an emerging scientific consensus, regulatory initiatives are currently ongoing (OECD, 2017) under an OECD remit with the commitment of implementing concepts and tools needed to identify DNT hazardous substances. Identifying reliable and efficient in vitro and in silico methods in line with the 3R principles (Replacement, Reduction and Refinement) (Russell and Burch, 1959) to identify and characterize DNT hazards for regulatory purposes is of high priority to predict human health concerns, as the majority of chemicals have not yet been tested for their DNT potential (Makris et al., 2009; Tohyama, 2016).

One prominent example of successful use of an alternative model for human hazard evaluation is the epidemic of microcephaly that occurred in Brazil. Zika virus (ZIKV) infection was soon identified as a likely culprit, but it also appeared that ZIKV infection could not be detected in all microcephaly cases and that the infection did not uniformly result in adverse effects on brain development (Albuquerque et al., 2016). However, the molecular mechanisms leading to microcephaly induced by ZIKV infection, recently substantiated in a case control study (de Araújo et al., 2017), were clearly evidenced using human neurospheres derived from human induced pluripotent stem cells (hiPSCs) (Garcz et al., 2017; Dang et al., 2016). Application of such human cell-based in vitro approaches for assessing chemicals that could potentially affect the developing brain seems logical.

A recent approach illustrates how in vitro and in silico bioactivity data can be combined with kinetics modeling to derive ‘risk’ estimates (Sipes et al., 2017). This approach, not yet applied to DNT, allows rapid estimations of possible interactions of chemical molecules with biological targets at environmentally relevant exposure levels. Such computational predictive approaches are highly attractive alternatives, as they can handle and integrate massive amounts and diverse types of information to facilitate toxicity predictions at the level of complexity of the intact human. In its report on Toxicity Testing in the 21st Century, the National Research Council (NRC, 2007, McCray et al., 2010), already 11 years ago called for the development of new approaches to human health risk assessment that would rely on mechanistic understanding of toxicity pathways using human in vitro models and computer-based modeling, rather than apical animal testing (Krewski et al., 2010). Knudsen et al. (2013) reiterated the recommendation that in silico approaches should be included in future toxicity assessments.

Progress for alternative DNT testing should be accelerated, in a manner fit for scientific and regulatory acceptance. In vitro screening programs have already been initiated. For example, the U.S. EPA ToxCast high-throughput screening assays program, where so far approximately 2000 chemicals have been examined for ~700 assay endpoints (Richard et al., 2016), and the US Federal Tox21 Program, which
has screened nearly 8500 chemicals in about 50 selected assays (Tice et al., 2013; Attene-Ramos et al., 2013). Unfortunately, few assays in these programs are directly relevant to brain development. These issues highlight the critical need for a global strategy that stimulates the development and application of alternative models for DNT testing (Leist et al., 2014; Bal-Price et al., 2018b).

The present special issue contributes to defining the state-of-the-art of currently available alternative approaches for DNT evaluation (Bal-Price et al., 2018a), and it also outlines how traditional animal testing could be improved by alignment of rodent testing with effects seen in children after neurotoxic exposures (Vorhees, 2018). The potential alternative approaches relevant to DNT testing are discussed including key neurodevelopmental processes and AOP-driven integrated approaches to testing and assessment (IATA) for DNT screening and prioritization (Bal-Price et al., 2018a, Sachana et al., 2018), application of non-mammalian models such as zebrafish (Geier et al., 2018; Padilla et al., 2018), developing a systems biology approach and an ontology-driven animal-free test battery for DNT testing (Hessel et al., 2018), the role in toxicant sensitivity of alterations in cellular metabolism during human neurogenesis (Delp et al., 2018) and a molecular species comparison using methods such as the ‘Neuro assay’ (Masjosthusmann et al., 2018).

Accordingly, the authors of this statement, which include stakeholders from regulatory agencies, academia and industry, and some of whom have contributed a manuscript to this special issue, recommend holders from regulatory agencies, academia and industry, and some of those tests should be evaluated in the regulatory context.

6. Closing remaining knowledge gaps through further research with the goal of developing more supportive and effective regulation. There is agreement on the DNT Community (Bal-Price et al., 2015, Fritsche et al., 2017) on the necessity for further international research on testing strategies, which will require funding by all stakeholders, including government, non-governmental organizations and industry.

We envisage that the present DNT special issue of TAAP on Alternative Approaches to Developmental Neurotoxicology (DNT) Evaluation will inspire both scientists and regulators to follow these recommendations and to develop rational and more efficient approaches to identify chemical exposures that may pose a risk to the developing brains of future generations.

Transparency document

The http://dx.doi.org/10.1186/s13063-018-0454-1 associated to this article can be found, in the online version

References

Albuquerque, M.F., Souza, W.V., Mendes, A.D., Lyra, T.M., Ximenes, R.A., Araújo, T.V., Braga, C., Miranda-Filho, D.B., Martelli, C.M., Rodrigues, L.C. (2016). Pyrroxyfen and the microcephaly epidemic in Brazil - an ecological approach to explore the hypothesis of their association. Mem. Inst. Oswaldo Cruz 111 (12), 774–776.

de Araújo, T.V.B., Ximenes, R.A.A., Miranda-Filho, D.B., Souza, W.V., Montarroyo, U.R., de Vazquez, E., di Cavalcanti, D., Cruz, S., Mazierovitch, C., Henriques, P., Albuquerque, Bezerra Jr., K.C., da Silva, P.M., Dhalia, C.R., Azevedo J., Mesquita E.T., Turchi Martelli, C.M., Cunha Rodrigues, L., 2017. Association Between Microcephaly, Zika Virus Infection, and Other Risk Factors in Brazil: Final Report of a Case-Control Study. www.thelancet.com/infection (Published online December 11, 2017). http://dx.doi.org/10.1016/S1473-3099(17)30772-7.

Aschner, M., Ceccatelli, S., Daneshian, M., Fritsche, E., Hasiwa, N., Hartung, T., Hopgood, H.T., Leist, M., Li, A., Mundy, W.R., Padilla, S., Piersma, A.H., Bal-Price, A., Seiler, A., Westerink, R.H., Zimmer, B., Lein, P.J., 2017. Reference compounds for alternative test methods to indicate developmental neurotoxicity (DNT) potential of chemicals: example lists and criteria for their selection and use. ALTEX 34 (1), 49–74.

Attene-Ramos, M.S., Miller, N., Huang, R., Michael, S., Itkin, M., Kavlock, R.J., Austin, C.P., Shinn, P., Simonov, A., Tice, R.X., Xia, M., 2013. The Tox21 robotic platform for the assessment of environmental chemicals—from vision to reality. Drug Discov. Today 15 (16), 716–723.

Bal-Price, A., Coecke, S., Costa, L., Crofton, K.M., Fritsche, E., Goldberg, A., Grandjean, P., Lein, P.J., Li, A., Lucchini, R., Mundy, W.R., Padilla, S., Persso, A.M., Seiler, A.E., Keysa, J., 2012. Advancing the science of developmental neurotoxicity (DNT): testing for better safety evaluation. ALTEX 29, 202–215.

Bal-Price, A., Crofton, K.M., Leist, M., Allen, S., Arand, M., Buetler, T., Delrue, N., Fitzgerald, R.E., Hartung, T., Heinenon, T., Hopgood, H., Benzekou, S.H., Lichtensteiger, W., Ogger, D., Paparella, A., Axelstad, M., Piersma, A., Rached, E., Schilter, B., Schmuck, G., Stoppin, I., Tongiorgi, E., Tiramani, M., Monnet-Tschudi, F., Wilks, M.F., Ylikomi, T., Fritsche, E., 2015. International stakeholder network (IATA) to improve developmental neurotoxicity (DNT) testing road map for regulatory purposes. Arch. Toxicol. 89, 269–287.

Bal-Price, A., Pistollato, F., Sachana, M., Bopp, S.K., Munn, S., Worth, A., 2018a. Strategies to improve the regulatory assessment of developmental neurotoxicity (DNT) using in vitro methods. In: TAAP DNT Special Issue.

Bal-Price, A., Hopgood, H., Crofton, K., Daneshian, M., Fitzgerald, R., Fritsche, E., Heinenon, T., Hogaard, S., Piersma, A., Sachana, M., Shaffer, T., Schilter, B., Taron, A., Monnet-Tschudi, F., Viviani, B., Waldmann, T., Westerink, R., Wilks, M., Witters, H., Zurich, M., Lein, M., 2018b. Recommendation and application of in vitro test readiness criteria: exemplified for developmental neurotoxicity (DNT). ALTEX (Submitted).

Baumann, J., Gaasmon, K., Masjosthusmann, S., Deloer, D., Bendt, F., Giersiefer, S., Fritsche, E., 2016. Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events. Arch. Toxicol. 90, 1415–1427.

Bennett, D., Bellinger, D.C., Birnbbaum, L.S., Bradman, A., Chen, A., Cory-Slechta, D.A., Engler, A.M., Fallin, M.D., Halladay, A., Hauser, R., Hertz-Picciotto, I., Kwiatkowski, C.F., Lanphear, B.P., Marquez, E., Marty, M., McPartland, J., Newschaffer, C.J., Payne-Sturges, D., Patauia, H.B., Perera, F.P., Ritz, B., Sass, J., Schantz, S.L., Webster, T.F., Whyatt, R.M., Woodruff, T.J., Zoeller, R.T., Androzek, L., Campbell, C., Conry, J.A., DeNicola, N., Gould, R.M., Hirtz, D., Hufnig, K., Landrigan, P.J., Lavin, A., Miller, M., Mitchell, M.A., Rubin, L., Schettler, T., Tran, H.L., Acosta, A., Brody, C., Miller, E., Miller, P., Swanson, M., Witherspoon, N.O., 2016. Project TENDR: targeting environmental neurodevelopmental risks the TENDR consensus statement. Environ. Health Perspect. 124 (7), A118–22. http://dx.doi.org/10.1289/ehp.1508950.

Björling-Poulsen, M., Andersen, H.R., Grandjean, P., 2008. Potential developmental neurotoxicity of pesticides used in Europe. Environ. Health 7, 50. http://dx.doi.org/10.1186/1476-069X-7-50.

Crofton, K.M., Mundy, W.R., Schairer, T.J., 2012. Developmental neurotoxicity testing: a path forward. Congenit. Anom. (Kyoto) 52 (3), 140–146.

Crofton, K., Fritsche, E., Yiikomi, T., Bal-Price, A., 2014. International stakeholder network (ISTNET): creating a developmental neurotoxicity (DNT) roadmap for regulatory purposes. ALTEX 31 (2), 223–224.

Dach, K., Bendt, F., Huebenthal, U., Giersiefer, S., Lein, P.J., Heuer, H., Fritsche, E., 2017. BDE-99 impairs differentiation of human and mouse NPCs into the oligodendroglial lineage by species-specific modes of action. Sci. Rep. 70 (20), 44861.
Fritsche, E., 2018. A transcriptome comparison of time-matched developing human, mouse and rat neural progenitor cells reveals human uniqueness. In: TAAP DNT Special Issue, (Submitted).

McCray, L., Meyer, O., Patterson, R.D., Pennie, W., Scala, R.A., Solomon, G.M., Stephens, M., Yager, J., Zeise, L., 2010. Toxicity testing in the 21st century: a vision and a strategy. J. Toxicol. Environ. Health B Crit. Rev. (2–4), 51–138.

McDonald, M.E., Paul, J.F., 2010. Timing of increased autistic disorder cumulative incidence. Environ. Sci. Technol. 44, 2112–2118.

Moser, V., Bailey, F., Bowers, W., Raffaello, K., Crofton, K., Gilbert, M., 2016. North American Free Trade Agreement (NAFTA) Technical Working Group on Pesticides (TWG) Developmental Neurotoxicity Study Guidance Document. https://www.epa.gov/sites/production/files/2017-02/documents/developmental_neurotoxicity_study_internal_guidance_document_final.pdf

National research council, 1984. Toxicity testing: strategies to determine needs and priorities. The National Academies Press, Washington, DC (ISBN 0-309-03433-7).

NRC – National Research Council, 2007. Toxicity Testing in the 21st Century: A Vision and a Strategy. The National Academies Press, London. http://dx.doi.org/10.17226/11970.

OECD, 2007. OECD Guidelines for the Testing of Chemicals/Section 4: Health Effects. Test No. 426: Developmental Neurotoxicity Study (ISBN: 9789264067394). pp. 26.

OECD, 2017. Report of the OECD/EFSA Workshop on Developmental Neurotoxicity (DNT): The Use of Non-Animal Test Methods for Regulatory Purposes. Environment, Health and Safety Publications Series on Testing and Assessment 242. (ENV/JM/MONO 63).

Padilla, S., Culbrett, M., Deborah, L.H., Olin, J., Jarema, K., Jensen, K., Tennant, A., 2018. Reviewer selection summary - screening for developmental neurotoxicity using larval zebrafish: assessing the preparation and the predictive capability. In: TAAP DNT Special Issue, (Submitted).

Richard, A.M., Judson, R.S., Hock, K.A., Grulke, C.M., Volarath, P., Thillaiahdrawajh, I., Yang, C., Rathman, J., Martin, M.T., Wambaugh, J.F., Knudsen, T.B., Kanchler, J., Mansouri, K., Putelievich, G., Williams, A.J., Little, S.B., Crofton, K.M., Thomas, R.S., 2016. ToxCast chemical landscape: paving the road to the 21st century toxicology. Chem. Res. Toxicol. (2016), 1225–1251.

Russell, W.M.S., Burch, R.L., 1959. The Principles of Human Experimental Technique. Methuen and Co. Ltd, London.

Sachau, M., Rotaki, A., Bal-Palace, A., 2018. Development of the adverse outcome pathway (AOP): chronic binding of antagonist to M-amyloid-β-aspartate receptors (NMDARs) during brain development induces impairment of learning and memory abilities of children. In: TAAP DNT Special Issue, (Submitted).

Schmidt, R.Z., Lehmann, M., Gutbier, S., Nemo, E., Noel, S., Smirnova, L., Forsby, A., Hescheler, J., Avcı, H.X., Hartung, T., Leist, M., Kobolák, J., Dinnány, A., 2017. In vitro acute and developmental neurotoxicity screening: an overview of cellular platforms and high-throughput technical possibilities. Arch. Toxicol. 91 (1), 1–53.

Sipes, N.S., Wambaugh, J.F., Pearce, R., Auerbach, S.S., Wetmore, B.A., Hsieh, J.H., Shapiro, A.J., Svoboda, D., DeVito, M.J., Ferguson, S.S., 2017. An intuitive approach for predicting potential human health risk with the Tox21 10k library. Environ. Sci. Technol. 51 (18), 10786–10796.

Smirnova, L., Hogberg, H.T., Leist, M., Hartung, T., 2014. Developmental neurotoxicity challenges in the 21st century and in vitro opportunities. ALTEX 31 (2), 129–156.

Tsuji, R., Crofton, K.M., 2012. Developmental neurotoxicity guideline study: issues with the alignment of rodent testing with environmental effects Test Guidelines OPPTS 870.6300 Developmental Neurotoxicity (ISBN: 9780870673944). pp. 73–256.

Toxicology and Applied Pharmacology 354 (2018) 3–6

Washington State Departments of Ecology and Health, 2009. State Lead Chemical Action Plan: Appendix E Income Effects from Reduced IQ. http://www.ecy.wa.gov/biblio/19070806.html.